NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

ATLnsider,

The mouse model used checkpoint inhibitors to achieve immune memory. I believe this is only needed when immune surveillance is lacking but since not all that much was known about DCs when the mouse model was set up it made sense to deal with the influx of checkpoint response from treatment instead of focus on spacing. Spacing of treatments is critical and that became understood better after the fact. My research indicated that spacing of treatments would need to be reduced for the Phase 2 portion of the trial and when proposed changes for Phase 2 were made they went with what I expected needed to be done which was no coincidence, it’s what needed to be done based on the science.
The next leg of Direct trialing will knock it out of the park but should be available even now in life threatening conditions because of known safety profile and signal of effect. “The process” stinks in cases like this and is nothing less than murderous. Soooo much learned since 2013. Best wishes.